{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:43:48Z","timestamp":1791607428755,"version":"4.3.4"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Conventional rosacea treatments are not uniformly pervasive, and the adverse reactions can potentially constrain their utility. The clinical use of JAK1 inhibitors upadacitinib and abrocitinib in the treatment of refractory rosacea has rarely been explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case report<\/jats:title><jats:p>We presented two cases of patients who received the JAK1 inhibitor upadacitinib and four cases of patients who received the JAK1 inhibitor abrocitinib for the treatment of refractory rosacea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The JAK1 inhibitors upadacitinib and abrocitinib may be promising medical options for patients with refractory rosacea. However, the long-term safety and efficacy of upadacitinib and abrocitinib require prospective controlled studies to assess them more comprehensively.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1416004","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T04:36:17Z","timestamp":1720499777000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Treatment of rosacea with upadacitinib and abrocitinib: case report and review of evidence for Janus kinase inhibition in rosacea"],"prefix":"10.3389","volume":"15","author":[{"given":"Ting","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.01.048","article-title":"Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea","volume":"50","author":"Wilkin","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16481","article-title":"Incidence and prevalence of rosacea: a systematic review and meta-analysis","volume":"179","author":"Gether","year":"2018","journal-title":"Br J Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/1346-8138.15301","article-title":"et al: Epidemiological features of rosacea in Changsha, China: A population-based, cross-sectional study","volume":"47","author":"Li","year":"2020","journal-title":"J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/jidsymp.2011.7","article-title":"et al: Clinical, cellular, and molecular aspects in the pathophysiology of rosacea","volume":"15","author":"Steinhoff","year":"2011","journal-title":"J Invest Dermatol Symposium Proc"},{"key":"B5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1590\/abd1806-4841.20163541","article-title":"Skin barrier in rosacea","volume":"91","author":"Addor","year":"2016","journal-title":"Anais brasileiros dermatologia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.1998.tb01739.x","article-title":"Demodex mites in acne rosacea","volume":"25","author":"Roihu","year":"1998","journal-title":"J cutaneous Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.04.041","article-title":"Emerging therapies in rosacea","volume":"69","author":"Layton","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.873","article-title":"Janus kinase inhibitors in dermatology: Part II","volume":"86","author":"Chapman","year":"2022","journal-title":"A Compr review. J Am Acad Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735","article-title":"et al: Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"B12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/1744666X.2019.1544892","article-title":"Upadacitinib for the treatment of rheumatoid arthritis","volume":"15","author":"Serhal","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/10600280221096713","article-title":"Abrocitinib: A new FDA-approved drug for moderate-to-severe atopic dermatitis","volume":"57","author":"Perche","year":"2023","journal-title":"Ann Pharmacother"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.037","article-title":"Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee","volume":"78","author":"Gallo","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.05.044","article-title":"Reliability of Clinician Erythema Assessment grading scale","volume":"71","author":"Tan","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13408","article-title":"Superiority of ivermectin 1% cream over metronidazole 0\u00b775% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial","volume":"172","author":"Taieb","year":"2015","journal-title":"Br J Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta psychiatrica Scandinavica"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192487","article-title":"The Rosacea-specific Quality-of-Life instrument (RosQol): Revision and validation among Chinese patients","volume":"13","author":"Deng","year":"2018","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nm1616","article-title":"et al: Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea","volume":"13","author":"Yamasaki","year":"2007","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.351","article-title":"TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes","volume":"131","author":"Yamasaki","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2121-8-14","article-title":"Induction of MMP-9 release from human dermal fibroblasts by thrombin: involvement of JAK\/STAT3 signaling pathway in MMP-9 release","volume":"8","author":"Wang","year":"2007","journal-title":"BMC Cell Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20160107","article-title":"Involvement of matrix metalloproteinases (MMPs) and inflammasome pathway in molecular mechanisms of fibrosis","volume":"36","author":"Robert","year":"2016","journal-title":"Biosci Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.141","article-title":"et al: molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of th1\/th17 pathways","volume":"135","author":"Buhl","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2006.00695.x","article-title":"Lymphangiogenesis and angiogenesis in non-phymatous rosacea","volume":"34","author":"Gomaa","year":"2007","journal-title":"J cutaneous Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12745","article-title":"Recombinant erythroid differentiation regulator 1 inhibits both inflammation and angiogenesis in a mouse model of rosacea","volume":"24","author":"Kim","year":"2015","journal-title":"Exp Dermatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.3390\/cancers14215262","article-title":"Inflammation as a therapeutic target in cancer cachexia","volume":"14","author":"Clamon","year":"2022","journal-title":"Cancers"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2013.08.015","article-title":"[Causes and differential diagnosis of flush]","volume":"35","author":"Lafont","year":"2014","journal-title":"La Rev medecine interne"},{"key":"B29","article-title":"Pathophysiological causes and clinical significance of flushing","volume":"50","author":"Ray","year":"1993","journal-title":"Br J Hosp Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.06.016","article-title":"Pruritus in allergy and immunology","volume":"144","author":"Yang","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/jidsymp.2011.9","article-title":"Rosacea: The cytokine and chemokine network","volume":"15","author":"Gerber","year":"2011","journal-title":"J Invest Dermatol Symposium Proc"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3892\/mmr","article-title":"The therapeutic effect of artesunate on rosacea through the inhibition of the JAK\/STAT signaling pathway","volume":"17","author":"Li","year":"2018","journal-title":"Mol Med Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S356551","article-title":"Multi-transcriptomic analysis and experimental validation implicate a central role of STAT3 in skin barrier dysfunction induced aggravation of rosacea","volume":"15","author":"Wang","year":"2022","journal-title":"J Inflamm Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32060","article-title":"et al: Toll-like receptor 2 regulates metabolic reprogramming in gastric cancer via superoxide dismutase 2","volume":"144","author":"Liu","year":"2019","journal-title":"Int J Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2018.3556","article-title":"et al: Rhododendron album Blume extract inhibits TNF-\u03b1\/IFN-\u03b3-induced chemokine production via blockade of NF-\u03baB and JAK\/STAT activation in human epidermal keratinocytes","volume":"41","author":"Park","year":"2018","journal-title":"Int J Mol Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"41779","DOI":"10.1038\/srep41779","article-title":"IL-17 induces reactive astrocytes and up-regulation of vascular endothelial growth factor (VEGF) through JAK\/STAT signaling","volume":"7","author":"You","year":"2017","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203535","article-title":"Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis","volume":"73","author":"Maurer","year":"2014","journal-title":"Ann rheumatic Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2017.4196","article-title":"The STAT-ROS cycle extends IFN\u2212induced cancer cell apoptosis","volume":"52","author":"Wang","year":"2018","journal-title":"Int J Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1365-2230.2006.02322.x","article-title":"The effect of azithromycin on reactive oxygen species in rosacea","volume":"32","author":"Bakar","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2009.04.007","article-title":"The molecular pathology of rosacea","volume":"55","author":"Yamasaki","year":"2009","journal-title":"J Dermatol Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.172403","article-title":"4-oxo-2-nonenal (4-ONE): evidence of transient receptor potential ankyrin 1-dependent and -independent nociceptive and vasoactive responses","volume":"337","author":"Graepel","year":"2011","journal-title":"vivo. J Pharmacol Exp Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.6.3051","article-title":"Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide","volume":"165","author":"Delgado","year":"2000","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15848","article-title":"Tofacitinib for the treatment of erythematotelangiectatic and papulopustular rosacea: A retrospective case series","volume":"35","author":"Sun","year":"2022","journal-title":"Dermatologic Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1002-1310.2023.01.016","article-title":"Jianwen Han: Evaluation of the efficacy of tofatinib in the treatment of 3 cases of refractory rosacea","volume":"45","author":"Yaqi Cao","year":"2023","journal-title":"Dermatol Venereol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S392280","article-title":"Tofacitinib for the treatment of steroid-induced rosacea","volume":"15","author":"Li","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1416004\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T04:36:21Z","timestamp":1720499781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1416004\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2024.1416004"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1416004","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"article-number":"1416004"}}